The North America Anti-Obesity Drugs Market would witness market growth of 9.3% CAGR during the forecast period (2023-2029).
The peripherally acting anti-obesity medications and the centrally acting anti-obesity drugs are the two primary subcategories that fall under the umbrella of the anti-obesity drug category. Anti-obesity drugs that work on the body's peripheral systems aid in weight loss without affecting the brain or hunger. The product inhibits the action of pancreatic lipase, which in turn impedes the hydrolysis of lipids in the gastrointestinal system and reduces the absorption of fat in the intestinal tract. There are many different kinds of medications, such as those that require a doctor's prescription and those that can be purchased without a doctor's permission.
These treatments could either be considered monotherapies or polytherapy, depending on how they are combined. On a national, regional, and international scale, obesity is a serious threat to public health. Because of an increase in the consumption of processed and unhealthy foods, a decrease in the amount of time spent being physically active, and a lack of understanding regarding the associated health hazards, the prevalence rate of obesity is increasing all over the region. As a consequence of this, the anticipated rise in demand for anti-obesity medication is anticipated to drive the expansion of the market.
According to Statistics Canada, the majority of adults in Canada are overweight or obese, with two out of every three falling into this category. In addition, the prevalence of childhood obesity has increased significantly over the past 25 years. The rise was observed in both male and female demographics and across all age brackets, except for those in the preschool category. Moreover, over 50% of Canadian children and adolescents do not engage in sufficient physical activity to achieve their maximum potential for growth and development. Thus, the growing prevalence of obesity among the regional population is expected to increase the demand and utilization of anti-obesity drugs propelling the market growth in the region.
The US market dominated the North America Anti-Obesity Drugs Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $781.6 million by 2029. The Canada market is poised to grow at a CAGR of 11.5% during (2023 - 2029). Additionally, The Mexico market would witness a CAGR of 11.2% during (2023 - 2029).
Based on Drug Type, the market is segmented into Prescription Drugs and Over The Counter Drugs. Based on Mechanism of Action, the market is segmented into Centrally Acting and Peripherally Acting. Based on Route Of Administration, the market is segmented into Oral Route and Subcutaneous Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Anti-Obesity Drugs Market is Projected to reach USD 3.1 Billion by 2029, at a CAGR of 10.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., Gelesis Holdings Inc. (PureTech Health), Currax Pharmaceuticals LLC (Currax Holdings USA LLC), Vivus LLC, CHEPLAPHARM Arzneimittel GmbH (Braun Beteiligungs GmbH) and KVK Tech, Inc.
By Drug Type
By Mechanism of Action
By Route Of Administration
By Distribution Channel
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
